# Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma

> **NCT06327269** · EARLY_PHASE1 · RECRUITING · sponsor: **Chang Gung Memorial Hospital** · enrollment: 40 (estimated)

## Conditions studied

- High Risk of Recurrence

## Interventions

- **DRUG:** Lenvatinib 10 mg

## Key facts

- **NCT ID:** NCT06327269
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-01
- **Primary completion:** 2024-12
- **Final completion:** 2026-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06327269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06327269, "Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06327269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*